Crossmark

Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand

Crossref DOI link: https://doi.org/10.1186/s13045-019-0733-6

Published Online: 2019-04-24

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mei, Lin

Zhang, Junran

He, Kai

Zhang, Jingsong
License Information

Text and Data Mining valid from 2019-04-24
More Information

Article History

Received: 20 February 2019

Accepted: 11 April 2019

First Online: 24 April 2019

Ethics approval and consent to participate

: Not applicable

: Not applicable

: Dr. Zhang has received consulting and speaker honorarium from AstraZeneca and consulting honorarium from Bayer.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.